DCR

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1 -
ipilimumab plus gp100 vs. gp100 1 -
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 certainty unassessable+19%
ipilimumab plus gp100 vs. ipilimumab alone 1 -
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 -
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 -
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessable+15%
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 -
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 -
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 -